Fulcrum Therapeutics, Inc. financial data

Symbol
FULC on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 24 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2431% % 17%
Debt-to-equity 6.3% % -21%
Return On Equity -30% % -668%
Return On Assets -28% % -680%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66,600,209 shares 23%
Common Stock, Shares, Outstanding 66,578,891 shares 23%
Entity Public Float $296,079,672 USD -4.1%
Common Stock, Value, Issued $67,000 USD 24%
Weighted Average Number of Shares Outstanding, Basic 63,355 shares 2.2%
Weighted Average Number of Shares Outstanding, Diluted 63,355 shares 2.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $56,103,000 USD -11%
General and Administrative Expense $28,666,000 USD -21%
Operating Income (Loss) $84,769,000 USD -287%
Net Income (Loss) Attributable to Parent $74,880,000 USD -670%
Earnings Per Share, Basic -1.18 USD/shares -638%
Earnings Per Share, Diluted -1.18 USD/shares -638%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $197,533,000 USD 239%
Other Assets, Current $69,000 USD
Assets, Current $357,480,000 USD 43%
Property, Plant and Equipment, Net $2,824,000 USD -28%
Operating Lease, Right-of-Use Asset $4,241,000 USD -25%
Other Assets, Noncurrent $538,000 USD 5280%
Assets $366,284,000 USD 40%
Accounts Payable, Current $1,592,000 USD 37%
Employee-related Liabilities, Current $4,312,000 USD 44%
Liabilities, Current $13,048,000 USD 18%
Operating Lease, Liability, Noncurrent $4,039,000 USD -37%
Other Liabilities, Noncurrent $197,000 USD 0%
Liabilities $17,284,000 USD -2.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax $174,000 USD 34%
Retained Earnings (Accumulated Deficit) $594,278,000 USD -14%
Stockholders' Equity Attributable to Parent $349,000,000 USD 44%
Liabilities and Equity $366,284,000 USD 40%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $15,257,000 USD 40%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $777,000 USD -102%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 66,578,891 shares 23%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $16,034,000 USD -211%
Deferred Tax Assets, Valuation Allowance $76,506,000 USD 48%
Deferred Tax Assets, Gross $78,360,000 USD 43%
Depreciation $1,390,000 USD -13%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $74,836,000 USD -691%
Property, Plant and Equipment, Gross $18,471,000 USD 1.7%
Operating Lease, Liability, Current $2,404,000 USD 10%
Deferred Tax Assets, Operating Loss Carryforwards $27,713,000 USD 1830%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $1,854,000 USD -36%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%